Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$243,787 | -$235,925 | -$130,904 | -$237,312 |
| Dep. & Amort. | $0 | $668 | $594 | $538 |
| Deferred Tax | $0 | $0 | $0 | -$53 |
| Stock-Based Comp. | $39,990 | $17,240 | $8,298 | $4,274 |
| Change in WC | $22,636 | -$8,899 | -$6,948 | -$961 |
| Other Non-Cash | -$1,775 | $63,638 | $14,064 | $158,094 |
| Operating Cash Flow | -$182,936 | -$163,278 | -$114,896 | -$75,420 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$117 | -$511 | -$817 |
| Net Acquisitions | -$775 | $0 | $0 | $0 |
| Inv. Purchases | -$312,223 | -$109,072 | -$226,369 | $0 |
| Inv. Sales/Matur. | $242,441 | $178,166 | $71,867 | $0 |
| Other Inv. Act. | $0 | -$4,590 | -$13,000 | $0 |
| Investing Cash Flow | -$70,557 | $64,387 | -$168,013 | -$817 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $13,694 | $233,375 | $0 | $960 |
| Stock Repurch. | $0 | -$491 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $7,909 | -$948 | $115,743 | $292,547 |
| Financing Cash Flow | $21,603 | $231,936 | $115,743 | $293,507 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$231,890 | $133,045 | -$167,166 | $217,270 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $375,251 | $242,206 | $409,372 | $192,102 |
| End Cash | $143,361 | $375,251 | $242,206 | $409,372 |
| Free Cash Flow | -$182,936 | -$163,395 | -$115,407 | -$76,237 |